Large Molecules Drug Substance CDMO Market Size (2024 - 2029)

Large Molecules Drug Substance CDMO Market Analysis

The Large Molecules Drug Substance CDMO Market size is estimated at USD 11.14 million in 2024, and is expected to reach USD 18.76 million by 2029, growing at a CAGR of 8.60% during the forecast period (2024-2029).

The market is driven by the increasing approval of molecules for drugs, the rising incidence of chronic and infectious diseases, the growing demand for biologics and biosimilars, and the increasing R&D investment by pharmaceutical companies for large molecules.

The increasing investment for the facility expansion that provides the large molecules of drug substance CDMO services is expected to boost the market during the forecast period. For instance, in January 2022, Alcami, a CDMO, reported a USD 10 million investment to expand its laboratory operation in Durham, North Carolina. The investment sought to expand the laboratory by over 6700 ft², incorporating state-of-the-art equipment. It aimed to bolster extensive molecule characterization capabilities for biologics at various development stages. The facility would support both parenteral manufacturing projects and independent analytical clients.

Moreover, strategic activities by the market players, such as mergers and acquisitions and partnership and services expansion, are expected to contribute to the market during the forecast period. For instance, in May 2023, Aurigene Pharmaceutical Services Limited, a subsidiary of Dr. Reddy's Laboratories, reported the construction of a new and advanced facility that will be used to develop and manufacture therapeutic proteins, antibodies, and viral vectors. This facility will be complemented by exclusive access to a large-scale GMP manufacturing facility with a drug substance capacity of 15,000 liters and fill-finish capabilities, allowing for seamless production of commercial quantities.

In September 2022, FUJIFILM Diosynth embarked on an expansion of its sizable microbial manufacturing facility in Billingham, the United Kingdom. The project, spanning an area of 1858 square meters (20,000 sq. ft), will cater to the increasing need for microbial development and production.

Hence, all the above factors mentioned, such as increasing investment for the production of large molecules of drug substances and strategic initiatives taken by the market players, are anticipated to grow the market during the forecast period. However, compliance issues while outsourcing and changing scenarios within developing countries are expected to restrain the market's growth during the forecast period.

Large Molecules Drug Substance CDMO Industry Segmentation

As per the scope of the report, the large molecules drug substance contract development and manufacturing organization (CDMO) market refers to the pharmaceutical and biotechnology industry sector that provides outsourcing services for developing and manufacturing large molecule drugs. Large molecules typically include proteins, peptides, monoclonal antibodies, and other biologically derived substances. The CDMO market for large molecules of drug substances is segmented by service, contract development, source, and geography. By services, the market is segmented into contract manufacturing and contract development. The market is segmented by source, such as mammalian, microbial, and others. By end user, the market is segmented as biotech companies, research institutes, and other end users. The market is segmented by geography as North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.